Recall alert: Orajel teething swabs pulled from shelves over potential fungal contamination
If you have a stash of teething remedies tucked into your medicine cabinet, it may be time to take a second look. Church & Dwight Co., Inc. has issued a voluntary nationwide recall of several swab-based products—including certain Orajel Baby Teething Swabs—due to possible fungal contamination in the cotton tip component.
The recall also includes two types of Zicam nasal swabs. According to the FDA's official alert, these fungi could pose a health risk, especially for children or individuals with weakened immune systems.
This isn't a reason to panic—but it is a moment to pause and take action.
Related: 1.7 million eggs recalled across 9 states after salmonella outbreak
All lot numbers of the following products are affected:
Orajel Baby Teething Swabs UPC: 310310400002Use: To soothe teething discomfort in babies and toddlers
Zicam Cold Remedy Nasal Swabs UPC: 732216301205Use: Homeopathic swab meant to shorten cold duration
Zicam Nasal AllClear Swabs UPC: 732216301656Use: Nasal cleansing swabs (discontinued in 2024)
Important: This recall does not include other Orajel or Zicam products, such as gels or RapidMelts.
Check your medicine cabinet for any of the products above. Look for the UPC code on the packaging.
Stop using recalled products immediately.
Visit www.churchdwightrecall.com or call 1‑800‑981‑4710 (Mon–Fri, 9 a.m.–5 p.m. ET) for a full refund.
Dispose of the product safely—do not donate or give it away.
Related: Check your fridge: Cucumber recall hits 15 states after salmonella outbreak
The FDA says the risk is highest for individuals with inflamed nasal tissue or weakened immune systems, as the fungal contamination could lead to serious infections, especially in the bloodstream.
But if your baby seems healthy and has shown no unusual symptoms, there's no immediate cause for alarm.
Still, if you've recently used a recalled swab call your pediatrician and mention the recall for guidance.
Recalls like these are unsettling—but they're also a sign that safety systems are working. If you've used these products, take a breath. Take the next step. You're doing the right thing by staying informed and responsive.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Vicarious Surgical delays robot timeline
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Dive Brief: Vicarious Surgical CEO Stephen From, who started his job last week, said Tuesday the company no longer expects to begin a clinical trial for its surgical robot by the end of this year and will instead focus on completing the design for the commercial version of the system. The company's shares slid more than 24% to end at $7.83 on Wednesday, according to Yahoo Finance. The clinical trial's timing will determine when the robot developer submits its de novo filing to the Food and Drug Administration, From said on Vicarious' second-quarter earnings call. Vicarious had planned to make its FDA submission in late 2026, after delaying the start of the trial. The company plans to conduct an assessment over about four to six weeks to gauge readiness for verification of the system, From said, adding he would work with Vicarious' board and investor base to evaluate the capital strategy for supporting its goals. Dive Insight: Vicarious, which counts large for-profit hospital operator HCA Healthcare and Bill Gates among its investors, is developing a single-port robotic system for abdominal procedures that will vie for market share with robot industry leader Intuitive Surgical. Vicarious is initially targeting hernia, gallbladder, gastrointestinal and gynecology procedures. From, who joined Vicarious as co-founder Adam Sachs moved into the role of president, said the single-port robotic market is still in its early stages, and he believes the company's differentiated platform and strong technical foundation will advance minimally invasive surgery. 'I see an industry here, which is dominated by one player, and I see a lot of others that are trying to copy what they're doing, and I saw this team wasn't,' said From. 'This is a project and this is a system and a company that is worth investing in for the long term, because this is a system that isn't just a copycat. This is a system that deserves market share.' Vicarious ended the second quarter with about $24 million in cash and expects its cash burn to be about $50 million for fiscal 2025. The company will likely need to seek non-dilutive financing to maintain operations or meaningfully cut expenses, BTIG analyst Ryan Zimmerman said in a note to clients Tuesday. 'It's clear that the company is undergoing a pause until further notice and [management] does not have a clear answer as to how this may impact longer-term timelines,' Zimmerman wrote. 'We think the potential likely path is that insiders may help support the company in order to give it some breathing room to get towards the finish line.' Recommended Reading Vicarious Surgical names Stephen From as next CEO
NBC News
6 hours ago
- NBC News
FDA warns about unapproved thyroid pills — then says it'll 'ensure access' to them
An unusual about-face that played out at the Food and Drug Administration over the last week illustrated the power of the 'Make America Healthy Again' movement, particularly with its focus on 'natural' drugs. Last Thursday, the agency published a statement saying it had concerns about the safety and effectiveness of unapproved thyroid medications made from animal tissue after it received complaints from patients and reports of adverse events. As a result, the FDA said it had notified drugmakers of its 'intent to take action' against the products, but added that it wouldn't do so immediately to give patients time to switch medications. 'The agency urges patients taking these unapproved animal-derived thyroid medications to treat hypothyroidism to talk to their doctor,' it wrote. The statement in and of itself was nothing surprising. Warnings about unapproved drugs are standard fare for the FDA. What followed also wasn't unheard of: social media backlash. But on Wednesday evening, FDA Commissioner Marty Makary seemingly reversed course, writing in a post on X that the FDA was committed to pursuing the first-ever approval of desiccated thyroid extract, pending results of the ongoing clinical trials. 'In the mean time, we will ensure access for all Americans,' he wrote. Five minutes later, Health Secretary Robert F. Kennedy Jr. responded. 'Love your approach of using gold standard science and common sense, @DrMarkaryFDA,' Kennedy wrote. So, what was this all about? Animal-derived thyroid pills The thyroid — a small, butterfly-shaped gland located at the front of the neck — helps regulate how the body uses energy by producing thyroid hormones. When it doesn't produce enough, it can lead to hypothyroidism, which can cause symptoms including unexplained weight gain, tiredness, sensitivity to cold, changes in menstrual cycles and symptoms of depression and anxiety, according to the Mayo Clinic. The condition is more common in women than men. The standard treatment is prescription thyroid hormone replacement therapy — basically, taking pills that contain the needed thyroid hormones. Typically one of two synthetic hormones, levothyroxine or liothyronine, or a combination of both, are prescribed. Some patients, however, turn to animal-derived thyroid pills either because they don't respond well to the synthetic versions or want to take something marketed as natural, said Dr. Michael Weintraub, an endocrinologist at NYU Langone Health in New York City. The pills — which aren't FDA-approved — are made from dried thyroid glands, usually from pigs, and are sold under brand names like Armour Thyroid, NP Thyroid, Nature-Thyroid and Natural Thyroid, according to the agency. About 1.5 million people in the U.S. were prescribed animal-derived thyroid pills in 2024, the FDA said. In the FDA statement warning against the animal-derived drugs, the agency said they may contain impurities that could result in infections and could also contain inconsistent levels of thyroid hormones, another risk for patients. Taking too much can cause unwanted effects, the FDA said, and too little could not be effective. The backlash In the days that followed the FDA's statement, patients and doctors took to social media to voice their opposition. 'BREAKING FDA set to BAN natural desiccated thyroid medications. Millions rely on these for hypothyroidism who don't respond well to synthetic thyroid pharmaceuticals,' read one post from Will Cole, a functional medicine doctor. 'Let your voice be heard. The FDA needs to change course on this one.' Dave Asprey, the founder of Bulletproof Coffee, a coffee and supplement brand, wrote: 'I found out I had very low thyroid levels in my mid-20s, and Hashimoto's. Normal synthetic thyroid drugs did not work. Natural thyroid extract worked very well and I have been taking it for more than 25 years without a problem.' Dr. Robert Malone — an anti-vaccine activist who was recently appointed by Kennedy to a vaccine advisory panel — called the decision 'terrible news — particularly for postmenopausal women.' He called on doctors and patients to contact the FDA in response. Andrew Nixon, a spokesperson for the Department of Health and Human Services, did not respond to a question about whether Makary's post on Wednesday was in response to social media backlash. When asked about whether the FDA would still take action against unapproved thyroid products, Nixon referred NBC News to the agency's statement last week, which said, 'FDA is not taking immediate action against manufacturers who make unapproved animal-derived thyroid medication to give patients time to transition to an FDA-approved medication to treat their hypothyroidism.' Nixon added that the agency 'will share additional information as it becomes available and as clinical trial results are released.' It's unclear which ongoing trials Makary and Nixon were referring to. lists a trial initiated by Walter Reed National Military Medical Center in 2012, but the trial's status is currently marked as 'unknown.' Allergan, the maker of Armour Thyroid, completed a trial in 2021 comparing its product to levothyroxine, a synthetic thyroid hormone. So, are these pills safe? Dr. Pieter Cohen, an associate professor of medicine at Harvard Medical School, said the FDA was correct to issue its initial warning about the thyroid pills, noting that the animal-derived pills aren't regulated by the agency and can pose significant risks. The FDA-approved synthetic versions usually replace one of two thyroid hormones: T4, the main hormone the thyroid produces, or T3, the active form of T4 that helps regulate energy and metabolism. Companies that make FDA-approved drugs must follow certain regulations, including consistent dosing. The animal-derived versions also contain the thyroid hormones, just like prescription medications, Cohen said, but because they're unregulated, the amount they contain can be all over the place. 'Getting too much or too little thyroid hormone has long-term health risks,' he said. 'If you take too much, it can damage your bones, it can damage your heart. If you take too little, if you're not getting enough, a number of problems can occur too, including mood problems, like depression.' Weintraub, of NYU Langone Health, said that tiny changes in thyroid hormone levels can have a big impact, so it's important to get the dosage right. He noted that pigs naturally have much higher levels of T3 than humans. 'It can lead to heart rhythm disturbances, which can be life-threatening. It can lead to bone degradation, which can lead to broken bones,' he said. Weintraub said he's had patients who took animal-derived thyroid pills who've had issues with sleeping, had sensitivity to heat or developed osteoporosis. Dr. Susan Spratt, an endocrinologist and senior medical director for the Population Health Management Office at Duke Health in North Carolina, however, said that it would be unfair for the FDA to 'suddenly yank' the animal-derived versions from the market 'without dedicated reasons that they are harmful.' Spratt said that the animal-derived pills have been around for decades as a prescribable drug. (Weintraub said the animal-derived drugs were 'grandfathered in,' meaning they were already on the market before current FDA standards for safety were put into place.) While Spratt said she prefers to prescribe the FDA-approved synthetic versions, the animal-derived versions offer an option for people who don't respond well to the synthetic ones. 'I would welcome NIH funding on why some patients don't feel as good on T4-only products,' she said. Weintraub said the synthetic versions don't 'necessarily help everyone's symptoms, but there's a more precise and safer way of treating that than resorting to a pig or cow thyroids.' He said patients who don't respond well to T4- or T3-only medications often do better on a combination of the two.
Axios
7 hours ago
- Axios
Colorado AG issues public advisory on kratom sales
The FDA is following Colorado's lead in cracking down on a potent compound found in kratom supplements: 7-hydroxymitragynine, or 7-OH. Why it matters: Products with 7-OH — which acts like an opioid and has been dubbed "legal morphine" by researchers — have surged in popularity. The big picture: In July, the FDA recommended more regulation of 7-OH products and warned consumers about their risks. Last month, the FDA also sent a letter to companies about the illegal marketing of 7-OH products, calling them potentially dangerous and unproven. The latest: Colorado Attorney General Phil Weiser issued a public advisory this week to alert consumers to "important new protections" related to kratom sales. "The law institutes new requirements for manufacturers, gives consumers new information about these products, and protects kids," Weiser said in a statement. Context: In May, state lawmakers approved a new law that toughens penalties for the sale of kratom by limiting it to those 21 and older and banning vape and candy-like products.
